Jeffrey R. Spencer, PhD is a co-founder of STATegics, Inc. with 20 years of experience in small molecule drug discovery and development. Prior to co-founding STATegics, he was senior director and head of discovery medicinal chemistry at Celera Genomics in South San Francisco, California, where he successfully advanced several small molecule discovery programs from screening to lead optimization. At Celera, he was responsible for a team of researchers focusing on the structure-based design of novel leads for respiratory and oncology targets, ultimately leading to an IND filing for cancer.

He was a postdoctoral fellow at the California Institute of Technology studying inhibitors of mammalian protein glycosylation and graduated with a PhD in organic chemistry from the University of California at San Diego.